Inato, the global clinical trial marketplace, recently announced the results from a survey of clinical research sponsors and sites to find out what the frustrations were, why the disappointing outcomes were so frequent - and crucially what the sponsors...
Abzena, an end-to-end CDMO for biologics and bioconjugates, will be presenting its latest AbZelect and AbZelectPRO cell line development (CLD) platforms and more at BIO 2024.
Daniel Spurgin, director of strategic partnerships at ReciBioPharm, unveiled the company's BIO 2024 plans and how the CDMO is set to flourish as more viral and nucleic acid therapeutics move to the clinic in the next two years.
Life sciences business Cytiva is set to launch its new platform, designed to accelerate the manufacturing process for autologous CAR-T cell therapies. Find out more about the company's priorities, market challenges, expansion plans and more.
Ahead of Bio 2024, we caught up with Matt Cokely, global technical consultant strategic leader, and Helen Gates, marketing director, at Ecolab Life Sciences to find out what the company is planning for the event and how it is navigating current challenges...
Before the industry is set to arrive in San Diego for Bio International 2024, we spoke with Dr. Harald Oberegger, global head business development at Novartis Contract Manufacturing. At the event, the company will be showcasing its cutting-edge technologies,...
Indica Labs, a leader in digital pathology solutions, has announced that it has received FDA clearance for its enterprise digital pathology platform, HALO AP Dx, for primary diagnosis.
Hazel Jones is the CEO at Enhanc3D Genomics. We sat down with her to discuss her leap of faith into 3D genomics, and how she is scaling the business and driving operational change.
Today (May 14) Everest Medicines, a biopharmaceutical company focused on progressive medicines and vaccines, announced the successful launch of small molecule Nefecon, a delayed-release capsule, in China, with the first prescription issued.
Roquette, a global leader in plant-based ingredients and a key provider of pharmaceutical and nutraceutical excipients, announced today (May 14) the launch of its innovative Lycagel Flex hydroxypropyl pea starch premix for softgel capsules.
The Global Heart Hub, an international alliance of heart patient organizations based in Ireland, has unveiled the first findings from their patient-led Insights from Patients living with Elevated Cholesterol (IPEC) data generation program.
Novigenix, a force in innovative cancer diagnostics, has announced a landmark partnership with the IMMUcan Consortium, a European leader in cancer research.
Sanofi, a global pharmaceutical giant, has announced a significant investment of over €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France.
In an interesting development in the field of rare disease therapeutics, Shionogi & Co., Ltd., and Maze Therapeutics, Inc. have sealed an exclusive worldwide license agreement for MZE001, a novel therapeutic candidate aimed at tackling Pompe disease.
Neurocrine Biosciences Inc. has initiated its phase 1 clinical study, marking a significant stride in the evaluation of NBI-1117567, an investigational small molecule, oral compound developed by Nxera Pharma.
A collaborative report released today (May 9) by Medicines Discovery Catapult (MDC), sheds light on the challenges facing the life sciences sector amidst recent economic turbulence.
Courtney Noah works in scientific affairs at BioIVT and after an amazing biology teacher in grade nine gave her a passion for science, she then followed the same teacher through her education.
PCI Pharma Services, a global leader in contract development and manufacturing, has embarked on the installation of crucial equipment for its latest sterile fill-finish facility at its Bedford, NH campus in Philadelphia.
Walgreens and Boehringer Ingelheim have joined forces in a move to enhance diversity and accessibility in clinical trials, aiming to make participation more inclusive and equitable.
In an article in Outsourcing Pharma last week, one of four pitches from Montreal’s non-profit organization, Centech was published as part of a startup miniseries.
Clerkenwell Health is proud to announce the launch of its foundation course for Psychedelic-Assisted Therapy, a comprehensive 30-hour program that brings together leading experts in the field.
Renée Aguiar-Lucander, CEO of Calliditas, is driving the advancement and launch of TARPEYO – the company’s medication targeting rare disease IgA nephropathy. We spoke with Renée about her journey from investment banking to science and the joy of bringing...
Owlstone Medical, a global leader in Breath Biopsy for early disease detection and precision medicine, has announced a funding to the tune of $6.5 million.
In the heart of Montreal sits the non-profit organization Centech, a place that supports projects and startups with high growth potential – from conception right through to commercialization, which it says is thanks to a bold, collaborative, and passionate...
Yesterday (April 29), Lonza, a global partner in the pharmaceutical, biotech, and nutraceutical sectors, announced the introduction of its AI-enabled Route Scouting Service (RSS).
OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.
Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).
In an extensive and enlightening chat with Prasad Raje, the CEO of LGM Pharma, OSP gained profound insights into the company's trajectory within the pharmaceutical industry.
Wuxi AppTec says recent allegations made by the US government that it has shared clients' data with Beijing without consent are ‘misleading’ and ‘inaccurate’.
A recent Deloitte report revealed that 36% of healthcare product launches fell short of achieving 80% of their sales targets within the first two years.
Last month, OSP was excited to write about One2Treat, a progressive startup specializing in digital health solutions, which has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.
From a child's chemistry set given to her by her grandfather to watching Open University maths programs, Karen Ooms seemed destined for a career in science.
Today (April 24), Astellas Pharma Inc. revealed that XTANDITM (enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent non-metastatic...
In a remarkable development, Front Line Medical Technologies Inc., an innovator in trauma care medical devices, has announced the attainment of CE marking for its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System).
In a major partnership aimed at accelerating research into Rett syndrome, a rare neurological disorder predominantly affecting girls, digital healthcare solutions company Vivalink, has joined forces with the Rett Syndrome Research Trust (RSRT).
Oncimmune Holdings plc, a prominent autoantibody profiling company catering to the pharmaceutical and biotechnology sectors, is expanding its horizons by delving into the realm of biomarkers for age-related diseases.
At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US.
After two major acquisitions, Biosynth is coming to CPHI North America ready to tell the industry about its enhanced capabilities and connect with new and existing customers.
Torbay Pharmaceuticals is a sterile injectable contract manufacturer and licence holder based in Devon, UK. We spoke with CEO Emma Rooth about the company's heritage and how it is striving to support the U.S. market.
